title: Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein.
abstract: Haloperidol has been shown to induce rapid and transient expression of c-fos messenger RNA and Fos protein in striatal neurons via dopamine D2 receptors. Regulation of the c-fos gene by cyclic AMP and Ca2+ has been shown to be dependent on a DNA regulatory element within its promoter that binds the constitutively expressed transcription factor cyclic AMP response element binding protein. Cyclic AMP response element binding protein binds to an oligonucleotide containing the calcium/cyclic AMP response element of the c-fos promoter sequence in striatal cell extracts; the amount of binding is not regulated by haloperidol treatment. We have previously shown that haloperidol induces cyclic AMP response element binding protein phosphorylation in the striatum. Here we show by intrastriatal injection of antisense oligonucleotides that haloperidol-induced Fos expression is dependent on cyclic AMP response element binding protein. Intrastriatal injections of phosphorothioate oligonucleotides, in antisense orientation to cyclic AMP response element binding protein messenger RNA, reduce levels of cyclic AMP response element binding protein and completely prevent haloperidol-mediated induction of Fos. Oligonucleotides in sense orientation have no such effect. We observed a markedly different time course of the Fos protein inhibition by cyclic AMP response element binding protein antisense oligonucleotides compared to c-fos antisense oligonucleotides. This most likely reflects the different half-lives of c-fos and cyclic AMP response element binding protein messenger RNA and proteins. Neither cyclic AMP response element binding protein nor c-fos antisense oligonucleotide injection reduced c-Jun immunostaining in the striatum. We conclude that haloperidol induces Fos via transcription factor cyclic AMP response element binding protein.
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: C
authors.initials: C
authors.lastname: Konradi
authors.forename: S
authors.initials: S
authors.lastname: Heckers
mesh_terms: D051698:Activating Transcription Factor 2; D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism*; D065127:Dopamine D2 Receptor Antagonists; D005786:Gene Expression Regulation; D006220:Haloperidol / Q000494:pharmacology*; D007150:Immunohistochemistry; D016350:Leucine Zippers / Q000502:physiology*; D008297:Male; D008969:Molecular Sequence Data; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D015290:Second Messenger Systems / Q000502:physiology; D014157:Transcription Factors
chemical_list: D051698:Activating Transcription Factor 2; D017362:Cyclic AMP Response Element-Binding Protein; D065127:Dopamine D2 Receptor Antagonists; D016760:Proto-Oncogene Proteins c-fos; D017448:Receptors, Dopamine D2; D014157:Transcription Factors; D006220:Haloperidol